argenex SE $ARGX Position Trimmed by Candriam S.C.A.

Candriam S.C.A. decreased its holdings in argenex SE (NASDAQ:ARGX) by 17.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 66,419 shares of the company’s stock after selling 13,701 shares during the quarter. Candriam S.C.A.’s holdings in argenex were worth $63,923,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its holdings in shares of argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares in the last quarter. Jennison Associates LLC lifted its position in shares of argenex by 3.4% during the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after acquiring an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of argenex by 1.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after acquiring an additional 2,579 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of argenex by 98.9% during the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after acquiring an additional 53,293 shares in the last quarter. Finally, Eagle Health Investments LP boosted its stake in shares of argenex by 21.7% during the 1st quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock worth $55,744,000 after acquiring an additional 13,606 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Up 3.6%

Shares of argenex stock opened at $927.21 on Friday. argenex SE has a 12 month low of $661.85 and a 12 month high of $1,072.75. The stock has a market cap of $58.31 billion, a PE ratio of 32.35, a price-to-earnings-growth ratio of 0.86 and a beta of 0.48. The business has a fifty day simple moving average of $930.66 and a 200-day simple moving average of $857.30.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Analysts expect that argenex SE will post 28.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ARGX. Wells Fargo & Company decreased their target price on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating on the stock in a report on Friday, October 23rd. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a report on Sunday, October 25th. Deutsche Bank Aktiengesellschaft reiterated a “neutral” rating on shares of argenex in a research report on Friday, October 9th. Piper Sandler increased their price target on argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Finally, Citigroup dropped their price target on argenex from $1,301.00 to $1,232.00 and set a “buy” rating on the stock in a research note on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,158.76.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs.

Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy.